{"Title": "Optimal priming of poxvirus vector (NYVAC)based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ ANRS VAC20 Phase I/II Trial", "Year": 2020, "Source": "PLoS Pathog.", "Volume": "16", "Issue": 6, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 1, "DOI": "10.1371/journal.ppat.1008522", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087320404&origin=inward", "Abstract": "\u00a9 2020 L\u00e9vy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.DNA vectors have been widely used as a priming of poxvirus vaccine in prime/boost regimens. Whether the number of DNA impacts qualitatively or quantitatively the immune response is not fully explored. With the aim to reinforce T-cell responses by optimizing the prime-boost regimen, the multicentric EV03/ANRS VAC20 phase I/II trial, randomized 147 HIV-negative volunteers to either 3xDNA plus 1xNYVAC (weeks 0, 4, 8 plus 24; n = 74) or to 2xDNA plus 2xNYVAC (weeks 0, 4 plus 20, 24; n = 73) groups. T-cell responses (IFN-\u03b3 ELISPOT) to at least one peptide pool were higher in the 3xDNA than the 2xDNA groups (91% and 80% of vaccinees) (P = 0.049). In the 3xDNA arm, 26 (37%) recipients developed a broader T-cell response (Env plus at least to one of the Gag, Pol, Nef pools) than in the 2xDNA (15; 22%) arms (primary endpoint; P = 0.047) with a higher magnitude against Env (at week 26) (P<0.001). In both groups, vaccine regimens induced HIV-specific polyfunctional CD4 and CD8 T cells and the production of Th1, Th2 and Th17/IL-21 cytokines. Antibody responses were also elicited in up to 81% of vaccines. A higher percentage of IgG responders was noted in the 2xDNA arm compared to the 3xDNA arm, while the 3xDNA group tended to elicit a higher magnitude of IgG3 response against specific Env antigens. We show here that the modulation of the prime strategy, without modifying the route or the dose of administration, or the combination of vectors, may influence the quality of the responses.", "AuthorKeywords": null, "IndexKeywords": ["Adolescent", "Adult", "AIDS Vaccines", "CD8-Positive T-Lymphocytes", "env Gene Products, Human Immunodeficiency Virus", "Female", "Genetic Vectors", "HIV Antigens", "Humans", "Interferon-gamma", "Male", "Middle Aged", "Poxviridae", "T-Lymphocytes, Helper-Inducer", "Vaccines, DNA"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85087320404", "SubjectAreas": [["Parasitology", "IMMU", "2405"], ["Microbiology", "IMMU", "2404"], ["Immunology", "IMMU", "2403"], ["Molecular Biology", "BIOC", "1312"], ["Genetics", "BIOC", "1311"], ["Virology", "IMMU", "2406"]], "AuthorData": {"36862529000": {"Name": "L\u00e9vy Y.", "AuthorID": "36862529000", "AffiliationID": "60023970, 60021567", "AffiliationName": "Assistance Publique-H\u00f4pitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service d\u2019Immunologie Clinique"}, "8841802700": {"Name": "Lacabaratz C.", "AuthorID": "8841802700", "AffiliationID": "60025066, 60106700", "AffiliationName": "Vaccine Research Institute, Universit\u00e9 Paris-Est Cr\u00e9teil, Facult\u00e9 de M\u00e9decine, INSERM U955"}, "57203687960": {"Name": "Leli\u00e8vre J.D.", "AuthorID": "57203687960", "AffiliationID": "60023970, 60021567", "AffiliationName": "Assistance Publique-H\u00f4pitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service d\u2019Immunologie Clinique"}, "14055137500": {"Name": "Wiedemann A.", "AuthorID": "14055137500", "AffiliationID": "60025066, 60106700", "AffiliationName": "Vaccine Research Institute, Universit\u00e9 Paris-Est Cr\u00e9teil, Facult\u00e9 de M\u00e9decine, INSERM U955"}, "8122113700": {"Name": "Surenaud M.", "AuthorID": "8122113700", "AffiliationID": "60025066, 60106700", "AffiliationName": "Vaccine Research Institute, Universit\u00e9 Paris-Est Cr\u00e9teil, Facult\u00e9 de M\u00e9decine, INSERM U955"}, "6603013397": {"Name": "Rieux V.", "AuthorID": "6603013397", "AffiliationID": "100613446", "AffiliationName": "ANRS"}, "57201119616": {"Name": "Ellefsen-Lavoie K.", "AuthorID": "57201119616", "AffiliationID": "60023561", "AffiliationName": "Centre Hospitalier Universitaire Vaudois (CHUV)"}, "7003826360": {"Name": "Bart P.A.", "AuthorID": "7003826360", "AffiliationID": "60023561", "AffiliationName": "Centre Hospitalier Universitaire Vaudois (CHUV)"}, "57204455293": {"Name": "Pantaleo G.", "AuthorID": "57204455293", "AffiliationID": "60023561, 60000239", "AffiliationName": "Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne"}, "8632775600": {"Name": "St\u00f6hr W.", "AuthorID": "8632775600", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit at UCL"}, "23482010600": {"Name": "McCormack S.", "AuthorID": "23482010600", "AffiliationID": "60022148, 60003108", "AffiliationName": "MRC Clinical Trials Unit at UCL"}, "17635344700": {"Name": "Launay O.", "AuthorID": "17635344700", "AffiliationID": "60000905, 60027185, 60021567", "AffiliationName": "Universit\u00e9 de Paris, Facult\u00e9 de m\u00e9decine Paris Descartes, Inserm, CIC 1417, F-CRIN I-REIVAC, Assistance Publique-H\u00f4pitaux de Paris, CIC Cochin Pasteur"}, "7404322878": {"Name": "Weber J.", "AuthorID": "7404322878", "AffiliationID": "60015150", "AffiliationName": "Imperial College London"}, "7007057996": {"Name": "Salzberger B.", "AuthorID": "7007057996", "AffiliationID": "60020016, 60030807", "AffiliationName": "University Hospital, Institute of Clinical Microbiology and Hygiene, University of Regensburg"}, "7402796151": {"Name": "Wolf H.", "AuthorID": "7402796151", "AffiliationID": "60020016, 60030807", "AffiliationName": "University Hospital, Institute of Clinical Microbiology and Hygiene, University of Regensburg"}, "7404299375": {"Name": "Wagner R.", "AuthorID": "7404299375", "AffiliationID": "60020016, 60030807", "AffiliationName": "University Hospital, Institute of Clinical Microbiology and Hygiene, University of Regensburg"}, "7005670198": {"Name": "Koelle D.M.", "AuthorID": "7005670198", "AffiliationID": "60015481, 60003625", "AffiliationName": "Department of Medicine, Department of Global Health, University of Washington, Fred Hutchinson Cancer Research Center"}, "7005651585": {"Name": "Montefiori D.C.", "AuthorID": "7005651585", "AffiliationID": "60005200, 60113147", "AffiliationName": "Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center"}, "26021617300": {"Name": "Yates N.L.", "AuthorID": "26021617300", "AffiliationID": "60005200, 60113147", "AffiliationName": "Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center"}, "6507517468": {"Name": "Tomaras G.D.", "AuthorID": "6507517468", "AffiliationID": "60005200, 60113147", "AffiliationName": "Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center"}, "12799324000": {"Name": "Gottardo R.", "AuthorID": "12799324000", "AffiliationID": "60003625", "AffiliationName": "Public Health Sciences Division, Fred Hutchinson Cancer Research Center"}, "37005811500": {"Name": "Mayer B.", "AuthorID": "37005811500", "AffiliationID": "60003625", "AffiliationName": "Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center"}, "56404987400": {"Name": "Ding S.", "AuthorID": "56404987400", "AffiliationID": "60100243", "AffiliationName": "EuroVacc Foundation"}, "7004041016": {"Name": "Thi\u00e9baut R.", "AuthorID": "7004041016", "AffiliationID": "115125176", "AffiliationName": "INRIA SISTM"}, "57191405992": {"Name": "Ch\u00eane G.", "AuthorID": "57191405992", "AffiliationID": "60021564", "AffiliationName": "CHU de Bordeaux, p\u00f4le de sant\u00e9 publique"}}}